Von Hippel-Lindau Tumor Suppressor (VHL) Antikörper

Antigen: Von Hippel-Lindau Tumor Suppressor (VHL)

Synonyme: RCA1, VHL1, HRCA1, Vhlh, BcDNA:RH61560, VHL, d-VHL, dVHL, dmVHL, Dmel\CG13221, CG13221, rca1, vhl1, hrca1, zgc:158722, DKFZp469K2019

Klonalität: Monoklonal (52A11)

Wirt: Maus

Reaktivität: Human

Applikation: ELISA, Western Blot (WB)

Produktnummer: ABIN361172

Produktbeschreibung

Weitere Bezeichnung: VHL

Immunogen: Recombinant VHL, Accession / GI number: NP_000542

Isotyp: TBD, kappa chain

Klon: 52A11

Beschreibung: Von Hippel-Lindau disease (VHL) is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in beta sheet (beta-domain) and a smaller a-helical domain (a-domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF).

Anwendungen

Applikationshinweise: Recommended dilution 1:500

Konzentration: 1mg/ml

Reinigung: The antibody was purified from mouse ascitic fluids by protein-G affinity chromatography

Buffer: In Phosphate-Buffered Saline (pH7.4) with 0.1% Sodium Azide

Lagerung: Store at -20°, Aliquot to avoid repeated freezing and thawing.

Forschungsgebiet: Hormone, Zytokine

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

anti-Von Hippel-Lindau Tumor Suppressor (VHL) antibody